CAR-T Therapies Should Impress EU Reimbursement Bodies

Health authorities in Europe have different approaches to evaluating the cost-effectiveness of new drugs, but in the case of the CAR-T therapies, they are likely to look favorably on factors such as their innovative nature, the small patient populations, and the dearth of effective treatments.

Benefit & Cost
EU reimbursement bodies are considering the cost-benefit of CAR-T therapies

The reimbursement difficulties faced in the UK by the CAR-T therapies Kymriah and Yescarta could be illustrative of the hurdles they will have to leap in other EU countries, which will have similar concerns over cost and the lack of comparator studies that have caused the health technology assessment (HTA) body NICE to issue preliminary guidance rejecting their routine use on the National Health Service.

On the other hand, HTA bodies in Europe are clearly impressed by the products, and if cost-effectiveness can be demonstrated...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Health Technology Assessment

More from Market Access